The anti-inflammatory and analgesic effects of norvedan a novel, non-steroidal agent.
Norvedan (2-phenyl-4-p-chlorophenyl-thiazole-5-ylacetic acid) has been investigated for anti-inflammatory activity using an 'adjuvant arthirits' in rats and for analgesic activity using a writhing test in mice and a pressure test in rats. At oral doses of 10, 30 and 100 mg/kg Norvedan caused a dose-related inhibition of the primary swelling of the paw injected with adjuvant and the development of secondary lesions was also inhibited. Writhing induced in mice by i.p. administered acetic acid was also reduced by Norvedan at oral doses of 30 mg/kg and above and the response was related to dose. Against pain induced in rats by application of pressure to an inflamed paw Norvedan alsp showed good activity which was present for at least 6 hr after dosing.
D000085:Acetates / Q000037:antagonists & inhibitors; D000698:Analgesia; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001168:Arthritis / Q000150:complications; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010653:Phenylbutazone / Q000627:therapeutic use; D051381:Rats; D013035:Spasm / Q000188:drug therapy; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors
D000085:Acetates; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013844:Thiazoles; C006124:fentiazac; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin